130 related articles for article (PubMed ID: 16027312)
1. Fabry disease: angiokeratoma, biomarker, and the effect of enzyme replacement therapy on kidney function.
Ries M; Schiffmann R
Arch Dermatol; 2005 Jul; 141(7):904-5; author reply 905-6. PubMed ID: 16027312
[No Abstract] [Full Text] [Related]
2. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease: recognition and management of cutaneous manifestations.
Möhrenschlager M; Braun-Falco M; Ring J; Abeck D
Am J Clin Dermatol; 2003; 4(3):189-96. PubMed ID: 12627994
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
[TBL] [Abstract][Full Text] [Related]
5. [Fabry's disease in children. Clinical and biological study of one family. Structure and ultrastructure of the kidney in a hemizygote and a heterozygote].
Desbois JC; Mazière JC; Gubler MC; Allaneau C; Verhaeghe MP; Herrault A
Ann Pediatr (Paris); 1977 Sep; 24(8-9):575-86. PubMed ID: 16211911
[No Abstract] [Full Text] [Related]
6. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity.
Allen LE; Cosgrave EM; Kersey JP; Ramaswami U
Br J Ophthalmol; 2010 Dec; 94(12):1602-5. PubMed ID: 20576773
[TBL] [Abstract][Full Text] [Related]
7. [Fabry disease: demographic data since introduction of enzyme replacement therapy].
Cybulla M; Walter K; Neumann HP; Widmer U; Schärer M; Sunder-Plassmann G; Jansen T; Rolfs A; Beck M
Dtsch Med Wochenschr; 2007 Jul; 132(28-29):1505-9. PubMed ID: 17607649
[TBL] [Abstract][Full Text] [Related]
8. Angiokeratomas, Fabry disease and enzyme replacement therapy: still a challenge.
Möhrenschlager M; Henkel V; Ring J
Br J Dermatol; 2005 Jan; 152(1):177-8; author reply 178-9. PubMed ID: 15656825
[No Abstract] [Full Text] [Related]
9. Biomarkers of Fabry disease nephropathy.
Schiffmann R; Waldek S; Benigni A; Auray-Blais C
Clin J Am Soc Nephrol; 2010 Feb; 5(2):360-4. PubMed ID: 19965549
[TBL] [Abstract][Full Text] [Related]
10. Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion.
Linthorst GE; De Rie MA; Tjiam KH; Aerts JM; Dingemans KP; Hollak CE
Br J Dermatol; 2004 Mar; 150(3):575-7. PubMed ID: 15030345
[TBL] [Abstract][Full Text] [Related]
11. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.
Ries M; Ramaswami U; Parini R; Lindblad B; Whybra C; Willers I; Gal A; Beck M
Eur J Pediatr; 2003 Nov; 162(11):767-72. PubMed ID: 14505049
[TBL] [Abstract][Full Text] [Related]
12. [Angiokeratoma corporis diffusum].
Schell H
MMW Munch Med Wochenschr; 1977 Jan; 119(2):47-8. PubMed ID: 401940
[No Abstract] [Full Text] [Related]
13. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease.
Beck M
Acta Paediatr Suppl; 2006 Apr; 95(451):43-6. PubMed ID: 16720464
[TBL] [Abstract][Full Text] [Related]
14. [Fabry disease: a little-known metabolic disorder with severe consequences].
Jansen T; Grabbe S
MMW Fortschr Med; 2006 Nov; 148(48):46-7. PubMed ID: 17615772
[No Abstract] [Full Text] [Related]
15. [Fabry disease--a provocation for pediatrics].
Hoffmann B; Mayatepek E
Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
[TBL] [Abstract][Full Text] [Related]
16. [Fabry disease: data from 4 families].
Ramselaar CG
Ned Tijdschr Geneeskd; 2001 Feb; 145(5):244-5. PubMed ID: 11219156
[No Abstract] [Full Text] [Related]
17. [Fabry disease--a diagnostic and therapeutic challenge].
Houge G; Skarbøvik AJ
Tidsskr Nor Laegeforen; 2005 Apr; 125(8):1004-6. PubMed ID: 15852071
[TBL] [Abstract][Full Text] [Related]
18. Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity.
Warnock DG; Remuzzi G; Brenner BM; Levin A; Wanner C
Clin J Am Soc Nephrol; 2010 Feb; 5(2):359. PubMed ID: 20019119
[No Abstract] [Full Text] [Related]
19. Misleading terms in Anderson-Fabry disease.
Weidemann F; Strotmann JM; Breunig F; Niemann M; Maag R; Baron R; Eggert AO; Wanner C
Eur J Clin Invest; 2008 Mar; 38(3):191-6. PubMed ID: 18257782
[TBL] [Abstract][Full Text] [Related]
20. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C.
Saadoun D; Asselah T; Resche-Rigon M; Charlotte F; Bedossa P; Valla D; Piette JC; Marcellin P; Cacoub P
Hepatology; 2006 Jun; 43(6):1337-45. PubMed ID: 16729318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
